Continuum Advisory LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 7.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,825 shares of the biopharmaceutical company's stock after acquiring an additional 5,185 shares during the period. Continuum

Burney Co. bought a new stake in Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 22,200 shares of the biopharmaceutical company's stock, valued at approximately $1,883,000. Other institutional investors also recently made changes to

Incyte Corporation (NASDAQ: INCY - Get Free Report) insider Thomas Tray sold 600 shares of Incyte stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $98.25, for a total value of $58,950.00. Following the completion of the transaction, the insider directly owned 22,973 shares in the

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.

TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.

INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.

December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, essential services, and key growth metrics.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discover.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma.